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ANALYSIS OF BROWN ADIPOCYTE-DERIVED VEGF-A 
ADAM WINSLOW LONG 
ABSTRACT 
Objective. While it has long been known that vascular endothelial growth factor A 
(VEGF-A) plays a role in vascular homeostasis, only recently have its effects been 
explored in adipose tissue. As perivascular adipose tissue (PVAT) is in close proximity 
with the aorta and coronary arteries and is known to contribute to vasodilation, it may 
influence vascular function via secretion of VEGF-A. The objective of this study is to 
analyze the effects of brown-adipocyte deletion of VEGF-A on circulating VEGF-A 
levels and distribution of VEGF-A isoforms. We hypothesize that ablation of VEGF-A in 
brown adipocytes will affect perivascular adipocyte and vascular function. 
Materials/Methods. Mice harboring a brown adipose-specific VEGF deficiency, 
UCP1cre.VEGFflox/flox mice, were maintained on a chow diet. Primary adipocytes were 
isolated from brown adipose tissue (BAT) and thoracic PVAT by collagenase digestion 
and culturing. Gene expression was measured by RT-PCR from RNA extracted from 
tissues of UCP1cre.VEGFflox/flox mice. Circulating and tissue VEGF-A levels were 
quantified by ELISA. 
Results. While VEGF-A ablation using the UCP1 promoter decreases VEGF- protein A 
levels in BAT and PVAT, it does not affect VEGF-A levels in the circulation. 
Conclusion. This study confirms the functional utility of the UCP1cre.VEGFflox/flox mouse 
model, as it selectively reduces VEGF-A levels in BAT and PVAT without affecting 
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other tissues or circulating levels. As previous studies using VEGF ablation in all adipose 
tissues demonstrate an impaired thermogenic response and brown-adipocyte dysfunction, 
further study of the brown adipose-specific mouse model is warranted. Because PVAT 
provides protection against vascular stiffness, modulation of VEGF-A in PVAT may be a 
viable treatment for obesity-associated vascular complications. 
 
  
  vii
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
INTRODUCTION .............................................................................................................. 1 
Overview .................................................................................................................... 1 
The Vascular Endothelial Growth Factor Pathway .............................................. 1 
VEGF in Human Disease.......................................................................................... 5 
VEGF Signaling in Multiple Tissue Types ........................................................... 10 
METHODS ....................................................................................................................... 18 
Animals .................................................................................................................... 18 
Tissue Isolation Protocol ........................................................................................ 18 
Primary Cell Isolation and Culture Protocol ....................................................... 18 
  viii
RNA Extraction ....................................................................................................... 19 
Real-Time Quantitative PCR ................................................................................. 20 
ELISA....................................................................................................................... 20 
RESULTS ......................................................................................................................... 21 
DISCUSSION ................................................................................................................... 27 
REFERENCES ................................................................................................................. 36 
CURRICULUM VITAE ................................................................................................... 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ix
LIST OF TABLES 
 
 
Table Title Page 
1 Phenotypic effects of VEGF-A Overexpression and Deletion 
 
8-9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  x
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Gene structure of human VEGF-A isoforms  
 
3 
2 Impaired vascular tone in Fabp4cre.VEGFflox/flox mice 13 
3 Generation of UCP1cre.VEGFflox/flox mice  
 
15 
4 Tissue VEGF and UCP1 concentrations in 
UCP1cre.VEGFflox/flox mice 
16 
5 Circulating VEGF concentrations in UCP1cre.VEGFflox/flox 
mice 
 
22 
6 PVAT primary cell culture and RNA extraction 23-26 
   
  
  xi
LIST OF ABBREVIATIONS 
 
BAT................................................................................................... Brown Adipose Tissue 
CVD ................................................................................................. Cardiovascular Disease 
DMEM ........................................................................ Dulbecco’s Modified Eagle Medium 
FA ................................................................................................................ Focal Adhesion 
FABP4..................................................................................... Fatty Acid Binding Protein 4 
GAPDH ..........................................................Glyceraldehyde 3-Phosphate Dehydrogenase 
HIF-1α ............................................................................ Hypoxia Inducible Factor 1-Alpha 
PE ................................................................................................................... Phenylephrine 
PGC-1α ........... Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha 
PI3K ...................................................................................... Phosphatidylinositol 3-Kinase 
PVAT ....................................................................................... Perivascular Adipose Tissue 
PWV ..................................................................................................... Pulse Wave Velocity 
SH .................................................................................................................. Src Homology 
UCP1 ................................................................................................... Uncoupling Protein 1 
VEGF .......................................................................... Vascular Endothelial Growth Factor 
VSMC ................................................................................... Vascular Smooth Muscle Cell 
WAT .................................................................................................. White Adipose Tissue 
 
  1
INTRODUCTION 
 
Overview 
 
 Despite recent advances in the development of cardiovascular medications and 
surgical techniques, cardiovascular disease (CVD) remains the leading cause of death 
worldwide. In the United States alone, CVD affects an estimated 26.6 million people and 
accounts for one in four deaths each year (CDC, 2015). Furthermore, approximately half 
of all Americans possess one of three main risk factors for CVD: smoking, high blood 
pressure, and high LDL cholesterol. The emergence of the obesity epidemic has only 
increased the prevalence of hypertension and dyslipidemia and further contributed to 
heart disease in this susceptible population. 
 
The Vascular Endothelial Growth Factor Pathway 
Vascular Endothelial Growth Factor (VEGF) is a potent mitogen that can bind to 
heparin sulfate and the tyrosine kinase VEGF receptors, VEGFR1 (Flt-1), VEGFR2 (Flk-
1), and the co-receptor neuropilin-1. Within the VEGF family, the VEGF-A protein has 
the greatest effects promoting angiogenesis, which is the outgrowth of new blood vessels 
from pre-existing vessels, and vasculogenesis, which is the de novo formation of new 
blood vessels. These vascular changes occur primarily due to interactions with VEGFR2, 
which is expressed on vascular endothelial cells and smooth muscle cells, as well as other 
cell types including neurons and Schwann cells (Sondell et al., 1999). Signaling through 
VEGFR2 occurs via ligand-binding and receptor dimerization, followed by 
transphosphorylation of tyrosine residues in the cytoplasmic kinase domain. 
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Subsequently, Src homology (SH) 2 domain proteins and adaptor proteins like Grb2 
mediate downstream responses, which can range from stimulation of nitric oxide 
production to Ca2+ mobilization, migration, and proliferation. VEGFR2 activity has also 
been tied to activation of PLC-γ, ERK, c-Src, and the phosphatidylinositol 3-kinase 
(PI3k)/Akt pathway that is involved in cell survival (Zachary et al., 2001). Many of these 
pathways and thus the overall function of VEGF-A have been analyzed in endothelial 
cells, which leaves other adjacent tissue types wholly understudied despite the fact that 
they may secrete or respond to VEGF-A and possess the ability to modulate endothelial 
cell or arterial signaling properties.  
Multiple isoforms of VEGF-A arise from alternative splicing of the pre-mRNA 
transcripts. The major isoforms possess either 121, 165, or 189 amino acids in humans 
and one less amino acid in mice (Arcondeguy et al., 2013; Fig. 1A-B). In mice, VEGF-
A164 appears to be the most widely expressed, but VEGF-A120 is also prevalent in the 
kidney while VEGF-A188 is highest in the lung (Ng et al., 2001). Of these isoforms, 
VEGF-A121 and VEGF-A165 are secreted and both are able to act in a paracrine or 
autocrine fashion. For example, VEGF-A165 plays a critical role in angiogenesis at 
cartilage growth plates and promotes endochondral ossification via an autocrine signaling 
loop in mammalian chondrocytes (Carlevaro et al., 2000). In the kidney, paracrine 
signaling of VEGF-A through VEGFR2 maintains glomerular filtration barrier integrity, 
demonstrated by ablation of VEGFR2 from glomerular endothelial cells as well as 
podocyte-specific overexpression of VEGF-A164, resulting in proteinuria and 
endotheliosis in the glomerulus (Sison et al., 2010). Taken together, the secretory VEGF 
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isoforms appear to be important for homeostatic control and development across a variety 
of tissues. 
 
A.
 
B. 
 
 
Figure 1: Gene structure of human VEGF-A isoforms. A) Exon map and VEGF-A 
gene length on chromosome 6p12. B) Exon composition of VEGF-A isoforms and 
their corresponding extracellular matrix affinity. (adapted from Arcondeguy et al., 
2013) 
In contrast to the secretory VEGF isoforms, VEGF-A189 is largely cell-associated 
due to tight binding with heparin proteoglycans in the extracellular matrix (Ferrara et al., 
1991). As shown in Fig. 1B, extracellular matrix affinity is directly correlated with 
  4
VEGF-A isoform length, which prevents longer isoforms such as VEGF-A189 from acting 
in a paracrine manner on adjacent tissues. As a result, VEGF-A189 was thought to play a 
lesser role in VEGF-induced angiogenesis than the other isoforms, however recent 
studies have shown that VEGF-A189 is capable of causing endothelial cell migration and, 
to some extent, proliferation (Herve et al., 2005; Park et al., 1993). In fact, one study 
even suggests that the VEGF-A189 isoform, likely through interactions with heparin 
sulfate proteoglycans and VEGFR2, is the driving force behind tumor angiogenesis in 
non-small cell lung cancer and may also play a role in the development of nascent 
glioblastomas and adenocarcinomas (Yuan et al., 2001). 
 As a growth factor heavily involved in vascular processes, VEGF-A is critical for 
the proper development of vascular organs. The ability of VEGF-A to produce organized 
vascular beds is not only due to its mitogenic effects on endothelial cells, but also due to 
the differential distribution of VEGF-A isoforms in developing tissues. In mice, VEGF-
A188 is highest in lung, heart, and liver because these are mesodermal-endodermal tissues 
whose early development require vasculogenesis, whereas VEGF-A120 and VEGF-A164 
are highest in the mesodermal-ectodermal tissues of the brain, eye, and kidney that utilize 
angiogenesis stemming from the budding vascular network (Ng et al., 2001). A global 
knockout of VEGF in a mouse model is embryonic lethal, suggesting VEGF is necessary 
for embryonic development. Interestingly, chimeric mice that only express VEGF-A120 
display defects in alveolar development due to decreased angiogenesis and increased 
vessel permeability. This suggests a need for the heparin-binding isoforms VEGF-A164 
and VEGF-A188 for capillary remodeling and maturation, as VEGF-A120 cannot produce 
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the extensive branching necessary for proper alveolarization beyond initial vessel growth 
(Carmeliet et al., 1996)(Ng et al., 2001). Taken together, these results indicate that the 
VEGF-A isoforms control discrete as well as overlapping functions. Part of this 
difference may also be due to the fact that, while VEGF-A120 and VEGF-A165 have 
similar affinity for isolated VEGFR2, the natural heterodimerization of the VEGF-A165-
binding neuropilin-1 with VEGFR2 potentiates the phosphorylating effect of VEGF-A165 
versus that of VEGF-A120 (Whitaker et al., 2001). While this required role of VEGF-A in 
embryonic development is well-understood, the manner in which VEGF contributes to 
vascular homeostasis in adult tissues remains to be fully elucidated. Furthermore, 
dysregulation of VEGF signaling can lead to significant vascular complications, 
particularly in the renal and cardiovascular systems.  
 
VEGF in Human Disease 
Major insights into the role that VEGF plays in maintaining a healthy vasculature 
come from attempts to modify VEGF in disease states, such as diabetes and cancer. 
Following its discovery in the 1980s and characterization in the 1990s, VEGF was 
thought to be one of many elusive factors that modulated tumor blood supply. A 
monoclonal antibody against VEGF was developed in 1993 that greatly reduced 
tumorigenesis in vivo, and in 2004 became the first FDA-approved, humanized 
angiogenesis inhibitor: bevacizumab (Avastin; Genentech) (Ferrara et al., 2004). 
Bevacizumab is still used to treat a variety of tumors, including lung, renal, brain, and 
metastatic colon cancers, demonstrating the broad tissue distribution and clinical 
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importance of VEGF.  
 While bevacizumab is effective at reducing cancer proliferation, off-target 
reductions in VEGF levels can damage otherwise healthy organs and result in significant 
side effects. In the kidney, for example, the glomerular microvasculature that filters the 
blood can be damaged and cause thrombotic microangiopathy and systemic hypertension 
in patients. This finding has been replicated by local VEGF ablation in mice (Eremina et 
al., 2008). These hypertensive side effects seen with use of VEGF inhibitors in cancer 
patients parallels the proteinuria and hypertension observed in the five percent of 
pregnant women who develop preeclampsia; interestingly, placental release of soluble, 
truncated VEGFR1 occurs in these women, such that VEGF is bound and sequestered 
without its downstream vasomodulating effects (Maynard et al., 2008). In some cases, 
such as dilative cardiomyopathy, VEGF-A165 and VEGF-A189 are downregulated, but it is 
not known whether this VEGF decrease is the cause or a result of the disease. 
Interestingly, in ischemic cardiomyopathy, VEGF and VEGF isoform expression is 
upregulated, however as ischemic hypoxia can induce VEGF transcription this is more 
likely an adaptive, protective response to injury rather than an instigator of dysfunction 
(Abraham et al., 2000). Observations from a VEGF deletion model that blocks the 
hypoxia response element, which results in motor neuron degeneration similar to 
amyotrophic lateral sclerosis (ALS), and use of VEGF to prevent cell death in a mouse 
model of Parkinson’s disease, support the notion that maintenance of VEGF expression is 
important for both neurons and the renal system (Storkebaum et al., 2004). Thus, 
adequate VEGF levels are critical to prevent capillary rarefaction and renal defects that 
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can result in vascular pathologies across organ systems.       
In contrast, glomerular VEGF is elevated in diabetes, which is the number one 
cause of end-stage renal failure in North America. It is not known whether the increase 
seen in patients is isoform-specific, however there is in vitro and in vivo evidence using 
VEGF-A165 overexpression that replicates the diabetes-induced renal damage. It is 
thought this occurs because VEGF-A165 is the dominant isoform expressed by both 
glomerular and tubular epithelial cells. Interestingly, renal podocytes exclusively express 
VEGFR2 in their cell body and foot processes, which also suggests that changes in 
VEGF-A165 levels could be most critical for renal homeostasis. While previous studies 
have demonstrated that global VEGF-A overexpression in mice results in proteinuria and 
other symptoms of diabetic nephropathy, a recent study that genetically deleted VEGF-A 
in mouse podocytes in an in vivo model of type 1 diabetes showed a concomitant increase 
in glomerular cell scarring, apoptosis, and overall mortality (Sivaskandarajah et al., 
2012). These results suggest that moderate physiologic elevations of VEGF-A in the 
diabetic glomerulus may be a protective adaptation, which helps explain both the renal 
side-effects observed with anti-VEGF cancer therapies as well as VEGF overexpression. 
Table 1 summarizes diseases and defects associated with VEGF deletion or 
overexpression: 
 
 
  
8
 
Table 1: Phenotypic effects of VEGF-A Overexpression and Deletion in Mouse Models 
VEGF-A Mouse 
Modification 
Area of Interest Physiologic Effects Citation 
    
Germline tetraploid embryonic 
stem cells, VEGF+/- 
 
VEGF heterozygosity Embryonic lethal Carmeliet et al. 
1996 
Exon deletion of VEGF164,188 
VEGF120/120 chimeric mice 
 
VEGF120 & lung 
development 
Decreased angiogenesis, retarded 
alveolarization 
Ng et al. 2001 
Bevacizumab, mAb for VEGF Off-target effects Thrombotic microangiopathy, 
systemic hypertension 
Eremina et al. 
2008 
Podocyte-specific DOX-inducible 
Podocin-rtTa.tetO-cre.VEGF-A  
Bevacizumab 
similarity 
Glomerular lesions, hypertension, 
proteinuria 
Eremina et al. 
2008 
Whole-body DOX-inducible 
tetO-cre.rosa-rtTa VEGFR2flox/flox 
VEGFR2 importance Glomerular endothelial cell injury, 
heart/liver damage 
Sison et al. 2010 
Podocyte-specific DOX-inducible 
Nephrin-Cre.rosa-rtTa.tetO-VEGF164 
 
Renal failure Proteinuria, endotheliosis Sison et al. 2010 
Podocyte-specific WT or STZ-treated 
Nphs2-rtTa.tetO-cre.VEGFflox/flox 
 
Elevated VEGF in 
diabetes 
STZ-mice: glomerular scarring, 
apoptosis, proteinuria 
Sivaskandarajah 
et al. 2012 
Adipose-specific Adpn-rtTa.TRE-VEGF  
and mcr84 mAb inhibition 
VEGF role in 
adipocytes 
Improves angiogenesis and 
glucose tolerance against HFD 
during adipose expansion  
Sun et al. 2012 
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Adipose-specific aP2.VEGF 
 
Elevated VEGF in 
diabetes 
 
Anti-inflammatory, insulin 
sensitive, anti-obesogenic 
 
Elias et al. 2012 
 
VEGF neutralization by  
adenoviral expression of soluble VEGFR1 
VEGF role in brown 
adipocytes 
Increased BAT apoptosis, 
mitochondrial degeneration 
Bagchi et al. 2013 
Adipose-specific ap2-cre.VEGFflox/flox 
and aP2-cre.rosa-rtTa.tetO-VEGF164 
VEGF role in 
adipocytes 
Reduced vascularization & 
inflammation with deletion, 
rescued by overexpression 
 
Sung et al. 2013 
Adipose-specific ap2-cre.VEGFflox/flox 
and adenoviral-VEGF-A rescue 
VEGF role in 
adipocytes 
BAT whitening and capillary 
rarefaction, rescued by local 
VEGF-A injection 
 
Shimizu et al. 
2014 
Brown adipocyte-specific  
UCP1-rtTa.TRE-VEGF-A 
VEGF role in brown 
adipocytes 
Improved thermogenesis, glucose 
metabolism, protects against HFD 
 
Sun et al. 2014 
Adipose-specific 
Fabp4cre.VEGFflox/flox 
VEGF role in 
adipocytes 
Impaired mitochondrial 
oxidation/structure/vascularization 
Mahdaviani et al. 
2016 
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VEGF Signaling in Multiple Tissue Types 
Though the role of adipocytes as secretory regulators of tissue function is 
becoming more appreciated, their role in cardiovascular function is not well understood. 
There is a need to study the interactions between adipocytes and other cell types, such as 
vascular smooth muscle cells. In the last decade, the existence of VEGF receptors in 
smooth muscle cells has been established, where before VEGF was thought to only act on 
vascular endothelial cells. While VEGF does not induce smooth muscle cell proliferation, 
it does appear to promote migration and act as a chemoattractant, which may be relevant 
for pathologic vascular processes, such as atherosclerosis and intimal invasion or scarring 
(Grosskreutz et al., 1999). As for adipose tissue, it is known that it expands following 
high caloric intake and requires increased vascularization to maintain normoxia and 
deliver nutrients within the fat. Obese mice display a deleterious reduction in VEGF-A 
and subsequent increase in adipose tissue hypoxia that promotes inflammation and 
insulin insensitivity. Adipocyte-localized doxycycline-inducible overexpression of 
VEGF-A during, but not after, adipose tissue expansion is able to ameliorate this negative 
metabolic shift that occurs as a result of VEGF-A dysregulation in obese ob/ob mice (Sun 
et al., 2012). Similarly, transgenic mice overexpressing VEGF-A are protected against 
insulin resistance due to a decrease in proinflammatory macrophage infiltration and 
improvements in glucose tolerance (Elias et al., 2012).      
 Perivascular adipose tissue (PVAT) surrounds vessels including the coronary 
artery and the aorta. Previous studies have demonstrated that PVAT impacts 
cardiovascular function via secretory interactions with the tunica externa and with the 
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aortic smooth muscle cells of the tunica media. Healthy PVAT has anti-contractile, 
vasodilating, and anti-inflammatory properties that can be attributed to its paracrine 
release of a host of vasoactive factors, such as adiponectin, a protein which enhances 
glucose metabolism and vasodilation of small arteries. In addition, PVAT also is a 
storage site of mesenchymal stem cells that can develop into adipocytes and vascular 
smooth muscle cells (Eringa et al., 2012). In obesity, however, aberrant PVAT expansion 
can induce macrophage infiltration, TNF-α release, reductions in adiponectin, and local 
hypoxia. Together, these changes can cause PVAT to promote a vasoconstrictive arterial 
state, which has also been implicated in the development of metabolic defects and 
atherosclerosis (Szasz et al., 2013).  
It has recently been shown that PVAT surrounding the thoracic aorta is similar to 
interscapular brown adipose tissue (BAT), which is a highly oxidative tissue, rich in 
mitochondria, in both morphology and gene expression (Fitzgibbons et al., 2011). One 
study has suggested that VEGF-A can induce BAT proliferation and promote cell 
survival via interactions with VEGFR1, VEGFR2, and heparin-sulfate binding by the 
VEGF-A164 and VEGF-A188 isoforms (Bagchi et al., 2013). These results may also apply 
to PVAT and thus PVAT regulation of human aortic function. Interestingly, studies of 
adipose-specific VEGF-A overexpression demonstrate significant upregulation of 
uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α) genes (Sun et al., 2012). These definitive molecular 
markers for BAT promote increased energy expenditure and may account for some of the 
metabolic improvements observed with VEGF-A overexpression in the context of obesity 
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and a high-fat diet. 
Published studies from our laboratory have shown that VEGF-A secretion from 
fat regulates BAT to a greater extent than white adipose tissue (WAT), as VEGF-A 
expression levels are greater in adipocyte precursors than hematopoietic stem cells or 
endothelial cells and are highest in BAT over WAT. Using a cre-lox system to ablate 
VEGF specifically in adipose tissues by targeting the fatty acid binding protein 4 (Fabp4) 
promoter, our lab generated Fabp4cre.VEGFflox/flox mice to analyze the functional 
consequences of VEGF-A deletion in adipocytes. Fabp4cre+.VEGFflox/flox mice displayed 
significant impairments in mitochondrial oxidation in vivo and of mitochondrial 
respiration in vitro, results which may be explained by the subsequent distortions in 
mitochondrial structure and decreased vascularization of the adipose tissue. This work 
identified that endogenous VEGF-A, acting in an autocrine manner, is necessary for 
regulation of BAT vascularization and thermogenic function (Mahdaviani et al., 2016). 
While this autocrine mechanism within BAT has thus been established, it remains 
unknown if paracrine VEGF-A signaling from BAT-like tissues, such as PVAT, occurs 
or affects vascular function. Preliminary data from our lab have demonstrated that 
Fabp4cre+.VEGFflox/flox mice exhibit increased collagen deposition in the thoracic aorta 
(Fig. 2A-B) consistent with the gradual pathogenesis of aortic remodeling. 
Fabp4cre+.VEGFflox/flox mice also demonstrate a diminished aortic relaxation response to 
acetylcholine (Fig. 2C), which is a functional measure of vascular tone that may be 
influenced by the observed increase in collagen deposition. These mice also display 
detrimental reductions in adiponectin expression in adipose tissue (Fig. 2D), which is a 
  13
crucial regulator of tissue vascularity and inflammation and which may predispose these 
mice to CVD. 
 
 
Figure 2: Impaired vascular tone in Fabp4cre.VEGFflox/flox mice. A) Representative 
aortic section stained with Masson’s Trichrome (left) and area of analysis (right). B) 
Collagen deposition quantification. C) Impaired relaxation in Fabp4cre+.VEGFflox/flox 
mice. D) Fabp4cre+.VEGFflox/flox mice display reductions in PVAT, BAT adiponectin 
(n=4) *P < 0.05 
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Despite the presence of this dysfunctional phenotype with adipose-specific loss of 
VEGF-A, we do not know the exact mechanism by which this occurs. We hypothesize 
that VEGF-A plays a central role in PVAT function and that brown adipocyte-specific 
ablation, accomplished by generation of UCP1cre.VEGFflox/flox mice of VEGF-A will 
result in impaired oxidative and vascular function in these tissues. UCP1cre.VEGFflox/flox 
mice were generated by cross-breeding VEGF homozygous floxed mice with and 
UCP1cre+ mice, followed by crossing the F1 progeny–heterozygous for VEGFflox and 
one cre+ and one cre- , to obtain UCP1cre-.VEGFflox/flox control and 
UCP1cre+.VEGFflox/flox experimental mice (Fig. 3). By using ELISA to analyze protein 
levels of VEGF-A across multiple tissue types, we were able to demonstrate that VEGF 
levels in lung and WAT were comparable between UCP1cre+.VEGFflox/flox and UCP1cre-
.VEGFflox/flox mice (Fig. 4A), but were reduced in BAT and PVAT of the 
UCP1cre+.VEGFflox/flox mice; therefore, our model for VEGF-A ablation is both organ- 
and genotype-specific. Though we observe a selective and targeted decrease in VEGF 
gene expression in BAT and PVAT, we also wanted to study UCP1 expression. 
UCP1cre+.VEGFflox/flox mice demonstrate decreased UCP1 expression in BAT and 
PVAT suggesting that VEGF does indeed regulate UCP1 transcription, likely through 
PGC-1α as has been previously described (Fig. 4B).  
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Figure 3: Generation of UCP1cre.VEGFflox/flox mice. Cross-breeding of multiple 
generations to select for UCP1cre.VEGFflox/flox mice.  
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A.  
 
B.  
Figure 4: Tissue VEGF and UCP1 Concentrations in UCP1cre.VEGFflox/flox mice.  
A) Concentration of VEGF across tissue types including lung, WAT, BAT, and PVAT as 
measured by ELISA. B) UCP1 gene expression decreases in the BAT and PVAT of 
UCP1cre+.VEGFflox/flox mice as expected and as measured by RT-PCR (cre-, n=7-9; cre+, 
n=6-9) *P < 0.01 
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In this thesis we will explore the presence and potential role of VEGF-A in 
thoracic PVAT and how this factor may affect overall aortic function in mice. We 
hypothesize that VEGF-A gene expression in PVAT may be similar to BAT and that 
brown adipocyte-specific ablation of VEGF-A in mice will alter PVAT molecular 
characteristics. 
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MATERIALS AND METHODS 
Animals 
For this study, mice were generated with brown adipose-specific VEGF-A ablation 
by crossing uncoupling protein-1 (UCP-1)-cre transgenic mice (obtained from Dr. Evan 
Rosen) and VEGFflox/flox mice (obtained from Genentech) on C57BL/6 genetic 
backgrounds to create experimental UCP1cre+.VEGFflox/flox mice. UCP1cre-.VEGFflox/flox 
mice were used as controls. 
 
Tissue Isolation Protocol 
Five different tissues were isolated from UCP1cre+.VEGFflox/flox and UCP1cre-
.VEGFflox/flox mice, including the interscapular brown adipose tissue (BAT), subcutaneous 
white adipose tissue (WAT), heart, lung, and thoracic perivascular adipose tissue (PVAT) 
using a dissecting microscope. Tissues were immediately snap frozen in liquid nitrogen 
for direct RNA extraction. 
 
Primary Cell Isolation and Culture Protocol 
Interscapular BAT and thoracic PVAT were also extracted for use in primary cell 
culture prior to RNA extraction. Briefly, freshly isolated tissues were placed in 
Dulbecco’s Modified Eagle Medium (DMEM) to maintain hydration. In a sterile hood, 
the cells were removed from the DMEM, shred with sterile scissors, and scraped into a 
falcon tube mixture of 5-6mg type 2 collagenase (Worthington) in 5ml HEPES buffer. 
Each cell-collagenase mixture was incubated in a shaking water bath for 20min at 37°C 
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and lightly vortexed every 5min. Using a syringe and 18.5G needle, the digested mixture 
was aspirated and filtered through a 100µm filter into a new falcon tube. After placing on 
ice for 10-20min to slow collagenase activity, this process was repeated with a 40µm 
filter and a minimum of 25mL DMEM was added through the filter to dilute the 
collagenase and further slow its activity. Mixtures were centrifuged at 1000RPM at 4°C 
for 10min, the supernatant was aspirated, and the remaining pellet was resuspended in 
300µl to 1.5ml BAT differentiation media. Note: the DMEM wash and centrifugation 
step can be repeated, but was often skipped due to low cell yields. Resuspended cells 
were then plated in 48- or 96-well plates at 8% CO2 and 37°C overnight, and washed with 
fresh media every other day thereafter for 7-8 days.  
 
RNA Extraction 
For cell cultures, RNA was extracted by direct lysis in culture plate wells with 
buffer RLT after removal of the BAT differentiation media and scraping with a sterile 
pipette tip. As cell cultures were not confluent, 350µl of buffer RLT was used in all 
cases. For tissues, RNA was extracted from the maximum amount of tissue available, 
wherein 600µl buffer RLT was used for ≤30mg tissue and 350µl buffer RLT was used for 
<20mg tissue; solid samples were disrupted and homogenized in a TissueLyser II with 
5mm stainless steel beads and then centrifuged for 3 min at 14,000 RPM. After lysis of 
each sample type, RNA extraction was followed according to the manufacturer’s 
instructions (Qiagen). 
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Real-Time Quantitative PCR 
RNA was transcribed to cDNA using a Qiagen QuantiTect® reverse transcription 
kit and BioRad T100™ Thermal Cycler according to manufacturer instructions. Gene 
expression in PVAT, BAT, and heart from UCPcre+.VEGFflox/flox and  
UCPcre-.VEGFflox/flox mice was measured with the ViiA™ 7 Real-Time PCR system. The 
reference gene for all samples was glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). Taqman and Qiagen expression assays were used for UCP1, VEGF-A, and 
VEGF isoform gene expression. Relative mRNA was quantitated using the ΔΔCT 
method, and expressed as fold change relative to UCPcre(-).VEGFflox/flox mice. Primer 
sequences were designed and validated by Zhang et al. (2015): 
Mouse VEGF common forward: 5’—GCCAGCACATAGAGAGAATGAGC—3’ 
Mouse VEGF120 reverse: 5’—CGGCTTGTCACATTTTTCTGG—3’ 
Mouse VEGF164 reverse: 5’—CAAGGCTCACAGTGATTTTCTTGG—3’ 
Mouse VEGF188 reverse: 5’—AACAAGGCTCACAGTGAACGCT—3’ 
 
ELISA 
 Lung, WAT, BAT, and PVAT tissue and cell samples from UCP1cre.VEGFflox/flox 
mice were homogenized in a TissueLyser II (Qiagen) and proteins were extracted. 
VEGF-A protein was quantified using a mouse VEGF-A ELISA kit according to 
manufacturer’s instructions (R&D Systems).  
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RESULTS 
Circulating and Tissue-specific VEGF Concentrations 
 Since we observed increased aortic collagen deposition and decreased adiponectin 
in Fabp4cre+.VEGFflox/flox mice (Fig. 2) with the most striking effects occurring in BAT, 
we used the brown-adipocyte specific UCP1cre.VEGFflox/flox mouse model to directly 
study the prevalence and importance of VEGF within BAT and PVAT to maintain their 
oxidative function and vascular homeostasis (Fig. 3). Furthermore, as there was a 
phenotypic difference between Fabp4cre+.VEGFflox/flox and Fabp4cre-.VEGFflox/flox mice, 
there was a need to exclude the possibility that our gene modifications were affecting 
circulating VEGF levels in addition to the expected local VEGF deletion, as that could 
contribute to the observed vascular impairments. We confirmed that any observed effect 
was due to our localized deletion of VEGF and not a result of a global change in VEGF 
levels by measuring circulating VEGF-A concentrations in UCP1cre+.VEGFflox/flox and 
UCP1cre-.VEGFflox/flox mice. As shown in Figure 5, there is no significant difference in 
circulating VEGF levels.   
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Figure 5: Circulating VEGF Concentrations in UCP1cre.VEGFflox/flox mice.  
Circulating concentration of VEGF in cre- and cre+ mice as measured by ELISA.  
(cre-, n=7-9; cre+, n=6-9) 
 
 
Primary Adipocyte Culturing and RNA Extraction 
 
 In order to analyze VEGF-A gene expression and distribution in 
UCP1cre+.VEGFflox/flox and UCP1cre-.VEGFflox/flox mice, we first needed to extract RNA 
from tissues or cell samples. Primary adipocyte cells, though difficult to obtain and to 
culture, would provide the greatest specificity for our research; isolated tissues, like BAT 
and PVAT, can be very heterogeneous as WAT, smooth muscle cells, and other 
extraneous cellular material can easily contaminate the samples. In contrast, primary 
brown or perivascular adipocytes, as detailed in the methods section, are more precisely 
isolated through collagenase digestion that breaks down extracellular matrices and 
filtration through cell strainers. Therefore, we initially cultured primary brown and 
perivascular adipocytes from UCP1cre-.VEGFflox/flox, UCP1cre+.VEGFflox/flox, and even 
0
10
20
30
40
50
Cre- Cre+
C
ir
cu
la
ti
n
g
 V
E
G
F
 (
p
g
/m
l)
  23
wild-type C57BL6/J mice. Photomicrographs of brown adipocyte cell culture are 
displayed in Fig. 6A.  RNA was extracted from primary cell cultures, and whole tissue 
samples of BAT, PVAT, and heart. RNA concentrations and purity, as measured by 
260/280nm absorbance ratio, were high in the isolated tissues and even in some of the 
UCP1cre-.VEGFflox/flox samples, indicating the RNA extractions were a success (Fig. 6B). 
At the same time, however, many of the cultured UCP1cre+.VEGFflox/flox adipocyte 
samples, though pooled from multiple wells and mice (n=2 per group), still yielded low 
RNA concentrations that have hampered further analysis. Efforts will be made in the 
future to improve primary adipocyte culture by modifying factors such as mouse age and 
reagent freshness to obtain maximally viable and confluent cell cultures in the future, as 
detailed in the Assessing Paracrine VEGF Signaling section of the discussion.      
 
A.  
          BAT Cre-           PVAT Cre- 
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B.  
Sample Source RNA 
Concentration 
(ng/ul) 
Absorbance 
(260nm/280nm) 
Tissue   
Cre- Heart 259.90 2.12 
Cre- Heart 113.70 2.11 
Cre- Heart 314.10 2.12 
Cre- Heart 356.50 2.12 
Cre- Heart 237.50 2.12 
Cre- Heart 268.30     2.14 
Cre+ Heart 383.20 2.13 
Cre+ Heart 314.80 2.12 
Cre+ Heart 327.10 2.14 
Cre+ Heart 271.90 2.13 
Cre+ Heart 346.50 2.12 
Cre- PVAT 263.00 2.12 
Cre- PVAT 143.10 2.10 
Cre- PVAT 205.90 2.10 
Cre- PVAT 235.90 2.12 
Cre- PVAT 245.00 2.1 
Cre- PVAT 254.30 2.12 
Cre- PVAT 292.90 2.11 
Cre+ PVAT 161.50 2.11 
Cre+ PVAT 215.10 2.11 
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Cre+ PVAT 279.40 2.13 
Cre+ PVAT 164.00 2.11 
Cre+ PVAT 301.00 2.11 
Cre- BAT 400.80 2.12 
Cre- BAT 106.30 2.10 
Cre- BAT 453.10 2.11 
Cre- BAT 282.70 2.11 
Cre- BAT 175.40 2.11 
Cre- BAT 435.20 2.12 
Cre- BAT 379.70 2.11 
Cre+ BAT 246.60 2.14 
Cre+ BAT 459.00 2.11 
Cre+ BAT 297.60 2.12 
Cre+ BAT 248.50 2.10 
Cre+ BAT 208.00 2.11 
Young PVAT 14.5 2.03 
Young PVAT 120 2.09 
Young PVAT 138.4 2.10 
Young PVAT 182.7 2.10 
Young PVAT 212.4 2.10 
Young PVAT 220.9 2.10 
Young PVAT 311.5 2.10 
Young PVAT 205.3 2.09 
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Young PVAT 171.1 2.10 
Aged PVAT 292.8 2.09 
Aged PVAT 163.5 2.08 
Aged PVAT 146.9 2.07 
Aged PVAT 277.3 2.09 
Cell Culture   
C57BL6/J BAT  47.8 2.03 
C57BL6/J PVAT 82.9 2.05 
Cre+ PVAT 12.30 1.98 
Cre- PVAT 42.60 2.11 
Cre+ BAT 111.80 2.09 
Cre- BAT 132.20 1.91 
Figure 6: PVAT primary cell culture and RNA extraction. A) Representative images, 
taken by phone through light microscope lens at 10X, of UCP1cre-.VEGFflox/flox 
differentiated primary brown adipocyte (left) and perivascular adipocyte (right) cultures 
on day 7. B) RNA extraction data categorized by sample source, cre status (red is 
negative, blue is positive), RNA concentration, and purity as measured by the 
260nm/280nm absorbance ratio (A: BAT and PVAT cre-, n=2; B: C57BL6/J, n=3)  
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DISCUSSION & FUTURE DIRECTIONS 
 This study was designed to explore the basic characteristics of the VEGF pathway 
and analyze the expression of VEGF-A in PVAT as a primary regulator of vascular and 
oxidative function. Our UCP1cre.VEGFflox/flox mouse model, which specifically ablates 
VEGF in brown adipocytes, will allow us to more precisely determine the extent to which 
brown adipocyte-derived VEGF directly affects vascular function without possible 
confounding from global deletion of WAT-derived VEGF. With this model, we can 
analyze the VEGF angiogenic pathway from release of VEGF-A from thoracic PVAT to 
its interactions with vascular smooth muscle cells and endothelial cells that play a role in 
atherosclerosis of the aorta and other major arteries. Future study of obesity- and age-
associated dysregulation of VEGF-A in PVAT may elucidate novel mechanisms that 
contribute to the pathogenesis of CVD and targets for next-generation vascular 
therapeutics. 
Assessing Paracrine VEGF Signaling 
 In the present study, we have explored the role that VEGF-A expression and 
secretion from adipose tissue plays in the coordination of angiogenesis and vascular 
homeostasis. Despite the success of other laboratory members to culture primary brown 
adipocytes isolated from UCP1cre.VEGFflox/flox mice, recent attempts have met with little 
success. Briefly, low cell yields, qualitatively defined as a lack of confluency in cultured 
primary brown adipocytes, were repeatedly observed upon collagenase digestion, 
adipocyte isolation, and immediate plating. Though experimenters varied through 
multiple run-throughs, improvements came from changes including: making fresh buffer 
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solutions, decreasing the time from dissection to plating, and eliminating one of the two 
wash steps. The greatest improvement was observed after using a syringe plunger to 
facilitate the movement of the mixture of cells in collagenase through the 100µm and 
40µm filters, followed by enhanced collection of the filtrate from the filter underside 
using a pipette. Though experimental conditions remained essentially identical to prior 
successful iterations of the primary brown adipocyte culturing protocol, RNA extraction 
of these non-confluent adipocyte cultures yielded low RNA concentrations that prevented 
proper use in subsequent RT-PCR analysis. Furthermore, our RT-PCR experiments with 
UCP1cre.VEGFflox/flox mouse cDNA, collected from RNA extracted directly from 
isolated BAT, WAT, and heart tissues, were often inconclusive and error-prone, but we 
have yet to identify the cause(s). These experimental inconsistencies have prevented 
reliable analysis from our more recent experiments and, as such, much of this manuscript 
has focused on prior work and future directions.    
 Beyond enhancing the reliability of our primary culture and RT-PCR protocol, in 
the future we would like to explore other aspects of VEGF-A and VEGF isoform 
expression. Once successful, we could use RT-PCR to measure VEGF isoform 
distribution across tissue types, including heart, BAT, and PVAT. With confluent 
cultures of primary brown and perivascular adipocytes from UCP1cre+.VEGFflox/flox and 
UCP1cre-.VEGFflox/flox mice, we could also analyze protein levels of VEGF-A120, VEGF-
A164, and VEGF-A188 as that would be a more direct method of analyzing the VEGF-A 
isoform distribution in brown-like adipocytes. It would be of interest to generate 
conditioned media from these primary cultures and treat vascular smooth muscle cells 
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(VSMCs) to analyze how VEGF ablation affects rates of proliferation and differentiation 
in culture as well as migration when measured by wound healing assay.   
VEGF and Aging 
 During the course of this study, we attempted to analyze VEGF-A isoform 
expression in the PVAT of young mice, aged 3-4 months, and older mice, aged 24 
months. Though experimental inconsistencies have hampered our ability to draw 
conclusions from our RT-PCR study of VEGF-A gene expression, addressing aging-
associated changes in VEGF expression across tissue types is critical to better our 
understanding of vascular pathologies, such as arteriosclerosis and cerebral 
microangiopathy, which often develop later in life. In the past decade, studies have 
identified that VEGF as well as VEGFR1 and VEGFR2 expression is reduced as cells age 
(Baffert et al., 2004; Iemitsu et al., 2006; Villar-Cheda et al., 2009; Wang et al., 2004). 
Aortic smooth muscle cells isolated from aged rabbits display a lack of proper 
upregulation of VEGF in hypoxic conditions, a process which is normally stimulated by 
the recruitment of the transcription factor hypoxia inducible factor 1α (HIF-1α). 
Decreases in HIF-1α protein levels and binding activity thus constitute a deleterious state 
that occurs with progressive aging and can lead to VEGF reductions and subsequent 
impairments in angiogenesis and tissue oxygenation following ischemia (Rivard et al., 
2000).  
 More recently it has also been shown that, compared to neonatal endothelial cells, 
aged human dermal microvascular endothelial cells exhibit reductions in VEGF 
  30
expression and angiogenesis. Expanding on previous work, the authors assert that this 
reduction is due to corresponding decreases in nuclear transport of the transcription 
factors P-STAT3 and P-CREB, which typically activate VEGF gene expression in 
concert with HIF-1α (Ahluwalia et al., 2014). Future therapeutic strategies will need to 
address this harmful decrease in HIF-1α activity. In fact, it has already been shown in 
aged mice that exercise can rescue HIF-1α activity and the ischemia-induced 
neovascularization needed for recovery via a phosphatidylinositol 3-kinase-dependent 
mechanism; pharmacologic or, indeed, physical activation of this upstream component of 
the VEGF pathway in elderly patients following ischemia may thus be a potent 
therapeutic tool to promote vascular regeneration (Cheng et al., 2010). Not all injuries are 
ischemic, however. It has also been shown that aged mice display defects in their ability 
to upregulate VEGF following mechanical injury to the sciatic nerve, illustrating the need 
to better understand all aspects of the VEGF angiogenic pathway in order to develop 
accurate and effective therapies (Pola et al., 2004).   
In Vivo/Ex Vivo Arterial Stiffness and Function 
 Since aberrant VEGF expression is observed with aging and we observe changes 
in the vasculature when we ablate VEGF in brown-adipocytes, we hypothesize that 
VEGF deletion will increase stiffening of major arteries, such as the thoracic aorta, that 
are prone to vascular damage. In this regard, alternative analyses of vascular and arterial 
function from a mechanical as well as molecular perspective may shed further light on 
negative, age-associated cardiovascular changes. Aortic stiffness, an independent risk 
factor and pre-symptomatic biomarker for cardiovascular disease, has enjoyed recent 
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attention in scientific research. On a macroscopic level, a less distensible aorta reduces 
energy absorption of the pressure pulse and results in a corresponding increase in 
circulatory pressure. At the tissue level, heterogeneity of the arterial architecture 
influences blood vessel function; for example, endothelial cells in the intima control 
differentiated vascular smooth muscle cell (dVSMC) tone in the media. In large arteries 
such as the aorta, dVSMC contraction moderately reduces lumen size and significantly 
enhances stiffness. Cellular and molecular regulation of these actin-myosin contractions 
occurs in many ways, but recent work has highlighted the role of nonmuscle cytoskeletal 
actin and integrin-mediated focal adhesions (FAs) between the cell and extracellular 
matrix. Specifically, tyrosine phosphorylation on FA proteins is a signal of FA turnover 
following establishment of a FA. FAs take part in mechanotransduction of external 
physical forces to internal biological signals, which may play a role in the development 
of cardiovascular disease when aberrantly regulated (Saphirstein and Morgan, 2014). As 
PVAT surrounds coronary arteries and are known to signal to dVSMC through VEGF-A 
in a paracrine manner, ablation of endogenous VEGF-A in UCP1cre+.VEGFflox/flox mice 
may impair vascular tone and FA homeostasis.  
 These basic physiological insights must be paired with biomechanic analyses to 
fully describe the cellular regulation of aortic stiffness and focal adhesions. At low 
pressure, distensible elastin maintains wall pressure, whereas at high pressure collagen 
reorganizes to stiffen the vessel wall and bear more of the load. Mechanically, blood 
vessels are nonlinear, anisotropic, and viscoelastic with hysteresivity independent of 
strain rate; in vivo the vessel wall is pre-stretched and stressed, all of which suggests 
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dynamic and complex regulation of the vessel architecture at a cellular level. Contrary to 
previous theories which suggested that dVSMC transiently adjusts vessel tension 
distribution between elastin and collagen, recent studies have indicated that age and 
hypertension increase the inherent stiffness of aortic SMCs. Building on our basic mouse 
model, we could include age as a variable and analyze aortic SMC stiffness in young as 
well as old UCP1cre+.VEGFflox/flox and UCP1cre-.VEGFflox/flox mice. With this setup, we 
would expect aged control mice to display inherent impairments in vessel elasticity, 
while aged experimental mice would possess even stiffer arteries. Lastly, we could 
confirm the critical role of paracrine-derived VEGF-A in maintaining vessel homeostasis 
by performing a gain-of-function experiment; to accomplish this, a microinfusion 
catheter would deliver exogenous VEGF-A to the perivascular adipose tissue and/or 
thoracic aorta, as has recently been validated in swine and humans, in an attempt to 
rescue vessel elasticity (Karanian et al., 2010; Owens et al., 2014).        
According to recent research, aortic stiffness can be classified as either functional 
or material. Material aortic stiffness is geometry-independent (e.g. Young’s Modulus), 
whereas functional aortic stiffness (e.g. impedance) is geometry- and material 
composition-dependent. Functional aortic stiffness is best measured by pulse wave 
velocity (PWV), which is defined as transit distance divided by transit time between 
carotid and femoral pressure waveforms in the vessel walls; one can also measure aortic 
characteristic impedance (Zc), which describes the ability of a vessel to limit flow caused 
by temporally varying gradients in pressure. The latter method is five-fold more sensitive 
to changes in diameter than the former, which is important when considering the vessel 
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context being studied. On the other hand, while material stiffness in vivo can be 
calculated from functional stiffness methods (using Bramwell-Hill or Moens-Korteweg 
equations), the results can be inaccurate due to a lack of control of geometric and loading 
factors. Thus, in vitro studies for material stiffness are considered superior, such as 
uniaxial ring stretching, biaxial tissue stretching, or pressurization of vessels, any of 
which could be performed on aortic rings or tissue isolated from UCP1cre+.VEGFflox/flox 
and UCP1cre-.VEGFflox/flox mice (Saphirstein and Morgan, 2014).  
 Increased functional aortic stiffness due to aging equilibrates impedance from the 
aorta and muscular arteries, which generates excessive pulse pressure and injures the 
microvasculature in high-flow, low-impedance organs such as the kidneys; this increased 
pressure itself can contribute to hypertrophy, promoting hypertension and further 
vascular insult. As mentioned previously, molecular mechanisms can also contribute to 
aortic stiffening. For example, elastin cannot be repaired and is thus highly susceptible to 
permanent crosslinking by advanced glycation end-products, calcification, and 
degradation by matrix metalloproteinases (Saphirstein and Morgan, 2014). One hypoxia-
independent mechanism of VEGFR2-mediated angiogenesis involves phosphorylation of 
Src kinase via SH2 docking. Once activated, Src blocks apoptosis via Raf-1 stimulation 
and promotes focal adhesion development and cell migration due to recruitment of FAK 
and paxillin proteins that are a component of the FA system (Rahimi, 2006). Contractile 
stimulation of dVSMCs or aortic rings with phenylephrine (PE), an alpha adrenergic 
agonist and vasoconstrictor, results in tyrosine phosphorylation of FAK and paxillin 
proteins (Min et al., 2012). 
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Future work could assess if there is an impairment in activation of these proteins, 
as measured by phosphotyrosine immunoblotting, in vitro with dVSMCs isolated from 
UCP1cre+.VEGFflox/flox mouse aortas compared to controls. Similarly, we could examine 
ex vivo the PE-induced isometric tension of aortic rings isolated from 
UCP1cre.VEGFflox/flox mice, which would be an improvement over previous work in our 
laboratory that only analyzed adipose-specific Fabp4cre.VEGFflox/flox mice. One 
interesting experimental variation would be to develop a VSMC-specific VEGFR2 
knockout mouse model that would mimic the impairments in isometric tension we expect 
to see in UCP1cre.VEGFflox/flox aortic rings and support the necessity of paracrine VEGF-
VEGFR2 signaling interactions for proper vascular tone.  
Lastly, in vivo one could assess functional aortic stiffness of 
UCP1cre.VEGFflox/flox mice using invasive pressure catheterization (Millar Instruments) 
of the thoracic aorta, as prior work from our laboratory failed to find stiffness differences 
from typical PWV measurements, which only target the WAT-like abdominal aorta, in 
Fabp4cre.VEGFflox/flox mice. As our new model of UCP1-targeted VEGF ablation should 
only affect the BAT-like thoracic aorta, results from thoracic pressure catheterization 
could be compared not only across cre+ and cre- mice, but also between thoracic and 
abdominal aortic stiffness. In any of these experiments, if a difference was identified it 
would shed light on a new role for BAT and PVAT-derived VEGF in the modulation of 
age-dependent aortic stiffness and SMC contractility from a mechanical as well as 
molecular standpoint. In the future, therapeutics may be developed that temporarily 
sequester substrates away from Src or that reduce vasoconstrictor induction of VSMC 
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contractile signaling and thereby lessen the tendency for aortic stiffening with age (Min 
et al. 2012).  
Based on this study and our previous work, we continue to hypothesize that 
VEGF plays a critical role in maintaining vascular homeostasis and modulating arterial 
function. The development of novel therapies that target VEGF pathways may therefore 
enhance existing treatments for cancer and age- or obesity-associated vascular diseases.    
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